Sunday, 21 April 2024
ACADIA Pharmaceuticals Inc.
-
Overlay
-
Indicators
-
Settings
-
Period
This is a real time view of the critical technical pivot points for ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) . The technical pivot points we look at all surround the stock price movement from the last 10-trading days through the last year.
more»
20:30 | 16/3/18
Voice Of Analysts
ACADIA Pharmaceuticals Inc. (ACAD) stock managed performance -0.16% over the last week and switched with performance of -14.56% throughout past one month period.
more»
02:30 | 16/3/18
Post Analyst
Investors making a wish list of stocks to watch should take a look at UDR, Inc. (NYSE:UDR). The stock is offering a price-to-sales ratio of 9.54.
more»
07:45 | 15/3/18
Stocks Gallery
In latest trading activity; ACADIA Pharmaceuticals Inc. (ACAD) snatched the consideration from Investors, when its current damaging picture was seen that is promoting bad performance.
more»
03:03 | 15/3/18
Stock Watch
After a recent check, ACADIA Pharmaceuticals Inc., (NASDAQ: ACAD)'s last month price volatility comes out to be 4.91% which for the week stands at 3.74%.
more»
01:45 | 15/3/18
StockNewsJournal
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) market capitalization at present is $3.11B at the rate of $24.98 a share. The firm's price-to-sales ratio was noted 25.85 in contrast with an overall industry average of 148.46.
more»
01:45 | 15/3/18
Post Analyst
Red Rock Resorts, Inc. (NASDAQ:RRR) popped in on a low volume red day. Volume on 13-Mar-18 came in at 0.57 million contracts.
more»
Breaking Down: ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) has hit extreme technical weakness -- watch the stochastics and technical oscillators for any kind of momentum signals if you are looking for a turnaround.
more»
02:18 | 14/3/18
Post Analyst
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), with a trailing 12-month price-to-sales ratio of 25.29, is now among the bigger bargains in its industry.
more»
04:45 | 11/3/18
StockNewsTimes
ACADIA Pharmaceuticals logo ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Director Daniel B. Soland acquired 7,000 shares of ACADIA Pharmaceuticals stock in a transaction dated Thursday, March 1st.
more»